## 1) The “700% Y/Y” headline is really a *product-market fit* signal, not just a comp ImmunityBio disclosed **~$113 million of full-year 2025 ANKTIVA net product revenue**, describing it as an **~700% year-over-year increase**, alongside **750% unit volume growth** and **20% quarter-over-quarter net product revenue growth**—a combination that points to broadening utilization (not merely price/mix or one-time stocking). ["$113 million… 700% increase"](0001326110-26-000025|1) ["750% unit sales"](0001326110-26-000025|1) ["20% quarter-over-quarter"](0001326110-26-000025|1) The more “between-the-lines” tell: the company also quantified **Q4 2025 product revenue growth versus Q4 2024** as a dollar increase driven by ANKTIVA sales—i.e., it’s framing the ramp as repeatable, operationally explainable demand rather than an accounting artifact. ["Product revenue, net increased $31.1 million"](0001326110-26-000025|1) --- ## 2) Regulatory expansion is quietly turning ANKTIVA into a multi-region commercial asset In the latest disclosures, ImmunityBio emphasized that ANKTIVA (bladder cancer) is now **authorized across four major regulatory jurisdictions—U.S., U.K., EU and Saudi Arabia—covering 33 countries**. ["authorized across four"](0001326110-26-000025|1) ["33 countries"](0001326110-26-000025|1) What’s “alpha” here is speed and sequencing: management explicitly highlighted building this **33-country footprint in under two years from initial FDA approval**, which implies a playbook for executing regulatory + commercial scale in parallel (and compressing the time between approval and monetization internationally). ["under two years"](0001326110-26-000025|1) The EU authorization was also disclosed as enabling commercial availability across **all 27 EU member states plus Iceland, Norway, and Liechtenstein**, taking the total to **33 countries**. ["conditional marketing authorization"](0001326110-26-000018|1) ["all 27… plus"](0001326110-26-000018|1) --- ## 3) The partnership model suggests operating leverage (and faster uptake) without building a massive owned footprint ImmunityBio didn’t just say “international opportunity”—it disclosed concrete go-to-market plumbing: * **Accord Healthcare**: a distribution partnership with **~85-person sales force across ~30 countries** (and separately described as **100+ commercial professionals across 30 European countries**), plus creation of an **Irish subsidiary (Dublin)** to support the European launch. ["distribution partnership with Accord"](0001326110-26-000025|1) ["85-person sales force"](0001326110-26-000025|1) ["deploy over 100"](0001326110-26-000025|1) ["Irish subsidiary in Dublin"](0001326110-26-000025|1) * **Saudi Arabia / MENA**: collaboration with **BioPharma & Cigalah**, plus formation of a **KSA subsidiary**—a structure that can accelerate “last-mile” execution in-region while the company stays focused on label expansion and supply. ["partnering with BioPharma & Cigalah"](0001326110-26-000025|1) ["formed a… subsidiary"](0001326110-26-000025|1) Read-through: this is a deliberate attempt to **turn regulatory wins into revenue quickly** while avoiding the time/cost of building a full ex-U.S. commercial organization from scratch. --- ## 4) Expansion beyond bladder cancer is the “optionality kicker” embedded in the latest release The company highlighted **Saudi FDA approval of ANKTIVA in combination with checkpoint inhibitors for metastatic NSCLC**, calling it the **first jurisdiction globally to authorize ANKTIVA outside of bladder cancer**, with **commercial launch planned within ~60 days**. ["approved… metastatic… NSCLC"](0001326110-26-000025|1) ["planned within 60 days"](0001326110-26-000025|1) ["first jurisdiction"](0001326110-26-000025|1) That matters because the disclosures also tie this to **planned accelerated-approval submissions in additional ex-U.S. jurisdictions** and **planned discussions with the U.S. FDA**—i.e., the company is explicitly positioning lung cancer and lymphopenia as potential next growth vectors rather than distant pipeline science. ["Submissions… planned"](0001326110-26-000025|1) ["discussions… U.S. FDA"](0001326110-26-000025|1) ["label expansion"](0001326110-26-000025|1) --- ## 5) Two “hidden” financial mechanics that sophisticated investors should model (not ignore) **A. Revenue ramp interacts with a sales-linked financing structure.** In its most recent 10‑Q on file, ImmunityBio disclosed a **Revenue Interest Purchase Agreement** under which Oberland receives **tiered quarterly payments (4.5%–10.0%) of worldwide net sales (excluding China)**, and it notes that changes in actual/forecast net sales can **materially impact** the liability and interest expense. ["tiered payments ranging"](0001326110-25-000139|0) ["worldwide net sales, excluding"](0001326110-25-000139|0) ["materially impact"](0001326110-25-000139|0) **B. Early gross margin may look better than steady-state.** The same 10‑Q states that **pre-approval ANKTIVA production costs were expensed in R&D** and therefore aren’t reflected in cost of sales, and it cautions that **cost of sales is expected to rise as those inventories are depleted**—a subtle reminder that “commercial momentum” and “economic profitability” won’t scale linearly. ["prior to receiving regulatory approval"](0001326110-25-000139|0) ["gross margin is higher"](0001326110-25-000139|0) ["cost of sales… increase"](0001326110-25-000139|0)

## 1) The “700% Y/Y” headline is really a *product-market fit* signal, not just a comp ImmunityBio disclosed **~$113 million of full-year 2025 ANKTIVA net product revenue**, describing it as an **~700% year-over-year increase**, alongside **750% unit volume growth** and **20% quarter-over-quarter net product revenue growth**—a combination that points to broadening utilization (not merely price/mix or one-time stocking). ["$113 million… 700% increase"](0001326110-26-000025|1) ["750% unit sales"](0001326110-26-000025|1) ["20% quarter-over-quarter"](0001326110-26-000025|1) The more “between-the-lines” tell: the company also quantified **Q4 2025 product revenue growth versus Q4 2024** as a dollar increase driven by ANKTIVA sales—i.e., it’s framing the ramp as repeatable, operationally explainable demand rather than an accounting artifact. ["Product revenue, net increased $31.1 million"](0001326110-26-000025|1) --- ## 2) Regulatory expansion is quietly turning ANKTIVA into a multi-region commercial asset In the latest disclosures, ImmunityBio emphasized that ANKTIVA (bladder cancer) is now **authorized across four major regulatory jurisdictions—U.S., U.K., EU and Saudi Arabia—covering 33 countries**. ["authorized across four"](0001326110-26-000025|1) ["33 countries"](0001326110-26-000025|1) What’s “alpha” here is speed and sequencing: management explicitly highlighted building this **33-country footprint in under two years from initial FDA approval**, which implies a playbook for executing regulatory + commercial scale in parallel (and compressing the time between approval and monetization internationally). ["under two years"](0001326110-26-000025|1) The EU authorization was also disclosed as enabling commercial availability across **all 27 EU member states plus Iceland, Norway, and Liechtenstein**, taking the total to **33 countries**. ["conditional marketing authorization"](0001326110-26-000018|1) ["all 27… plus"](0001326110-26-000018|1) --- ## 3) The partnership model suggests operating leverage (and faster uptake) without building a massive owned footprint ImmunityBio didn’t just say “international opportunity”—it disclosed concrete go-to-market plumbing: * **Accord Healthcare**: a distribution partnership with **~85-person sales force across ~30 countries** (and separately described as **100+ commercial professionals across 30 European countries**), plus creation of an **Irish subsidiary (Dublin)** to support the European launch. ["distribution partnership with Accord"](0001326110-26-000025|1) ["85-person sales force"](0001326110-26-000025|1) ["deploy over 100"](0001326110-26-000025|1) ["Irish subsidiary in Dublin"](0001326110-26-000025|1) * **Saudi Arabia / MENA**: collaboration with **BioPharma & Cigalah**, plus formation of a **KSA subsidiary**—a structure that can accelerate “last-mile” execution in-region while the company stays focused on label expansion and supply. ["partnering with BioPharma & Cigalah"](0001326110-26-000025|1) ["formed a… subsidiary"](0001326110-26-000025|1) Read-through: this is a deliberate attempt to **turn regulatory wins into revenue quickly** while avoiding the time/cost of building a full ex-U.S. commercial organization from scratch. --- ## 4) Expansion beyond bladder cancer is the “optionality kicker” embedded in the latest release The company highlighted **Saudi FDA approval of ANKTIVA in combination with checkpoint inhibitors for metastatic NSCLC**, calling it the **first jurisdiction globally to authorize ANKTIVA outside of bladder cancer**, with **commercial launch planned within ~60 days**. ["approved… metastatic… NSCLC"](0001326110-26-000025|1) ["planned within 60 days"](0001326110-26-000025|1) ["first jurisdiction"](0001326110-26-000025|1) That matters because the disclosures also tie this to **planned accelerated-approval submissions in additional ex-U.S. jurisdictions** and **planned discussions with the U.S. FDA**—i.e., the company is explicitly positioning lung cancer and lymphopenia as potential next growth vectors rather than distant pipeline science. ["Submissions… planned"](0001326110-26-000025|1) ["discussions… U.S. FDA"](0001326110-26-000025|1) ["label expansion"](0001326110-26-000025|1) --- ## 5) Two “hidden” financial mechanics that sophisticated investors should model (not ignore) **A. Revenue ramp interacts with a sales-linked financing structure.** In its most recent 10‑Q on file, ImmunityBio disclosed a **Revenue Interest Purchase Agreement** under which Oberland receives **tiered quarterly payments (4.5%–10.0%) of worldwide net sales (excluding China)**, and it notes that changes in actual/forecast net sales can **materially impact** the liability and interest expense. ["tiered payments ranging"](0001326110-25-000139|0) ["worldwide net sales, excluding"](0001326110-25-000139|0) ["materially impact"](0001326110-25-000139|0) **B. Early gross margin may look better than steady-state.** The same 10‑Q states that **pre-approval ANKTIVA production costs were expensed in R&D** and therefore aren’t reflected in cost of sales, and it cautions that **cost of sales is expected to rise as those inventories are depleted**—a subtle reminder that “commercial momentum” and “economic profitability” won’t scale linearly. ["prior to receiving regulatory approval"](0001326110-25-000139|0) ["gross margin is higher"](0001326110-25-000139|0) ["cost of sales… increase"](0001326110-25-000139|0)